Targeted drug tested for Hard-to-Treat blood disorder

NCT ID NCT03011372

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This study tested an oral drug called pemigatinib in people with a rare and aggressive type of blood cancer caused by a specific genetic change (FGFR1 rearrangement). The goal was to see if the drug could effectively control the disease and was safe to use. It involved 47 participants whose cancer had returned after other treatments or who were not candidates for a stem cell transplant.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Azienda Ospedaliero-Universitaria Careggi (Aouc)

Florence, 50134, Italy
Centre Leon Berard

Lyon, 69373, France
Chu de Nice - Hospital L Archet

Nice, 06202, France
City of Hope National Medical Center

Duarte, California, 91010, United States
Emory University - Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Franciscan St. Francis Health

Indianapolis, Indiana, 46237, United States
Guys and St Thomas Nhs Foundation Trust

London, SE1 9RT, United Kingdom
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Saint Louis

Paris, 75475, France
Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus

Vienna, 01140, Austria
Inselspital - Universitaetsspital Bern

Bern, 03010, Switzerland
Johannes Wesling Klinikum Minden

Minden, 32429, Germany
Kindai University Hospital

Osaka, 589-8511, Japan
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Medical University of Vienna

Vienna, 01090, Austria
Ntt Medical Center Tokyo

Tokyo, 141-8625, Japan
Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz

Linz, 04010, Austria
Ospedale Papa Giovanni Xxiii

Bergamo, 24127, Italy
Oxford University Hospitals Nhs Foundation Trust

Oxford, OX3 7LE, United Kingdom
Princess Margaret Cancer Center

Toronto, Ontario, M5G 2M9, Canada
Stanford Cancer Institute

Stanford, California, 94305, United States
Universitair Ziekenhuis (Uz) Leuven

Leuven, 03000, Belgium
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole

Toulouse, 31059, France
Universitatsklinikum Halle (Saale)

Halle, 06120, Germany
Universitatsklinikum Jena

Jena, 07740, Germany
Universitatsklinikum Leipzig

Leipzig, 04103, Germany
Universitatsspital Zurich

Zurich, 08091, Switzerland
University Hospital Mannheim

Mannheim, 68167, Germany
University Medical Center Rwth Aachen

Aachen, D-52074, Germany
University of Utah

Salt Lake City, Utah, 84112, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Weill Cornell Medical Centers

New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.

MPN (MYELOPROLIFERATIVE NEOPLASMS)